These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33373063)

  • 1. Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
    Brown JR; Walker SR; Heppler LN; Tyekucheva S; Nelson EA; Klitgaard J; Nicolais M; Kroll Y; Xiang M; Yeh JE; Chaudhury M; Giaccone ZT; Fernandes SM; Jacobsen ED; Fisher DC; Freedman AS; Davids MS; Supko JG; Wu C; Frank DA
    Am J Hematol; 2021 Apr; 96(4):E95-E98. PubMed ID: 33373063
    [No Abstract]   [Full Text] [Related]  

  • 2. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
    Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
    Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
    Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
    Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.
    Khan MW; Saadalla A; Ewida AH; Al-Katranji K; Al-Saoudi G; Giaccone ZT; Gounari F; Zhang M; Frank DA; Khazaie K
    Cancer Immunol Immunother; 2018 Jan; 67(1):13-23. PubMed ID: 28875329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.
    Kaymaz BT; Selvi N; Gündüz C; Aktan C; Dalmızrak A; Saydam G; Kosova B
    Ann Hematol; 2013 Jan; 92(2):151-62. PubMed ID: 23053176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
    Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.
    Liu FT; Jia L; Wang P; Farren T; Li H; Hao X; Agrawal SG
    Clin Cancer Res; 2016 May; 22(10):2462-9. PubMed ID: 26712690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
    Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
    Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
    BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
    Pallasch CP; Schwamb J; Königs S; Schulz A; Debey S; Kofler D; Schultze JL; Hallek M; Ultsch A; Wendtner CM
    Leukemia; 2008 Mar; 22(3):585-92. PubMed ID: 18079738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
    Morabito F; Filangeri M; Sculli G; Oliva B
    Haematologica; 1998 Nov; 83(11):1046-8. PubMed ID: 9864930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective toxicity of persian gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia b lymphocytes by direct mitochondrial targeting.
    Salimi A; Motallebi A; Ayatollahi M; Seydi E; Mohseni AR; Nazemi M; Pourahmad J
    Environ Toxicol; 2017 Apr; 32(4):1158-1169. PubMed ID: 27404045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
    Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
    Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells.
    Hubmann R; Hilgarth M; Schnabl S; Ponath E; Reiter M; Demirtas D; Sieghart W; Valent P; Zielinski C; Jäger U; Shehata M
    Br J Haematol; 2013 Mar; 160(5):618-29. PubMed ID: 23278106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
    Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
    Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
    Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.